Page 76

Revista Medica de Chile Enero 2016

ARTÍCULOS DE INVESTIGACIÓN 72 Linfonodo centinela isotópico en cáncer de mama - P. Humeres et al VS, Shriver C, et al. The sentinel node in breast cancera multicenter validation study. N Engl J Med 1998; 339 (14): 941-6. 17. Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial.Ann Surg Oncol 2010; 17 (7): 1854-61. 18. Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E, et al. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005). J Natl Cancer Inst 2008; 100 (7): 462-74. 19. Quan ML, Hodgson N, Lovrics P, Porter G, Poirier B, Wright FC. National adoption of sentinel node biopsy for breast cancer: lessons learned from the Canadian experience. Breast J 2008; 14 (5): 421-7. 20. Heneghan HM, Prichard RS, Devaney A, Sweeney KJ, Malone C, McLaughlin R, et al. Evolution of breast cancer management in Ireland: a decade of change. BMC Surg 2009; 9: 15. 21. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 2006; 106 (1): 4-16. 22. Ravdin PM, De Laurentis M,Vendely T, Lark GM. Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst 1994; 86 (23): 1771-5. 23. Povoski SP, Olsen JO, Young DC, Clarke J, Burak WE, Walker MJ, et al. Prospective randomized clinical trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol 2006; 13 (11): 1412-21. 24. Hill AD, Tran KN, Akhurst T, Yeung H, Yeh SD, Rosen PP, et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg 1999; 229 (4): 528- 35. 25. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomized phase 3 trial. Lancet Oncol 2010; 11 (10): 927-33. 26. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al.The sentinel node in breast cancer-a multicenter validation study. N Engl J Med 1998; 339 (14): 941-6. 27. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997; 15 (6): 2345-50. 28. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 1997; 349 (9069): 1864-7. 29. Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276 (22): 1818-22. 30. Borgstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S, et al. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998; 186 (3): 275-83. 31. Turner RR, Chu KU, Qi K, Botnick LE, Hansen NM, Glass EC, et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 2000; 89 (3): 574-81. 32. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220 (3): 391-8; discussion 398-401. 33. Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2014; 32 (13): 1365-83. 34. Olson JA Jr, McCall LM, Beitsch P, Whitworth PW, Reintgen DS, Blumencranz PW, et al. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol 2008; 26 (21): 3530-5. 35. Andersson Y, Frisell J, Sylvan M, de Boniface J, Bergkvist L. Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. J Clin Oncol 2010; 28 (17): 2868-73. 36. de Boer M, van Dijck JA, Bult P, Borm GF, Tjan-Heijnen VC. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst 2010; 102 (6): 410-25. 37. Shahar KH, Buchholz TA, Delpassand E, Sahin AA, Ross MI, Ames FC, et al. Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer 2005; 103 (7): 1323-9. 38. Chen RC, Lin NU, Golshan M, Harris JR, Bellon JR. Internal mammary nodes in breast cancer: diagnosis and implications for patient management-a systematic review.J Clin Oncol 2008; 26 (30): 4981-9. Rev Med Chile 2016; 144: 66-73


Revista Medica de Chile Enero 2016
To see the actual publication please follow the link above